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Abstract: Therapeutic gait interventions for individuals with Duchenne Muscular Dystrophy
(DMD) should be based on understanding how movement of the individual is affected
and whether different clusters of individuals, determined by clinical severity, differ. Gait
indexes have been developed to synthesize the data provided by the three-
dimensional (3D) gait analysis such as the Gait Deviation Index (GDI) and the Gait
Profile Score (GPS) where the gait variable score (GVS) can be calculated. The
objective this study was to evaluate the potential use of the GDI and GPS and MAP
using data from 3D gait analysis of DMD patients.  The dimension 1 score of the Motor
Function Measurement defined the groups that composed the cluster analysis. Twenty
patients with DMD composed 2 groups according to the cluster analysis (Cluster 1,
n=10; Cluster 2, n=10). Three-dimensional gait analysis was conducted where GDI,
GPS and GVS (pelvic tilt/obliquity; hip flexion-extension/ adduction-abduction/ rotation;
knee flexion-extension; ankle dorsiflexion-plantarflexion, foot progression angle) were
calculated. Cluster 1 group presented lower hip flexion-extension and lower pelvic
obliquity when compared with Cluster 2 group (p<0.05). There was no difference
between groups for GDI, GPS total and maximum isometric muscle strength of the
lower limbs (p>0.05). This study showed that GVS could detect alterations on the
parameters obtained using three-dimensional gait analysis for those DMD patients
separated according to motor function regarding pelvic and hip kinematic patterns. The
rehabilitation of patients with DMD is recommended from the early stages of the
disease (as Cluster 1, with > MFM) with the hip joint being the therapeutic target.
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Therapeutic gait interventions for individuals with Duchenne Muscular Dystrophy (DMD) 
should be based on understanding how movement of the individual is affected and whether 
different clusters of individuals, determined by clinical severity, differ. Gait indexes have been 
developed to synthesize the data provided by the three-dimensional (3D) gait analysis such as the 
Gait Deviation Index (GDI) and the Gait Profile Score (GPS) where the gait variable score (GVS) 
can be calculated. The objective this study was to evaluate the potential use of the GDI and GPS 
and MAP using data from 3D gait analysis of DMD patients.  The dimension 1 score of the Motor 
Function Measurement defined the groups that composed the cluster analysis. Twenty patients 
with DMD composed 2 groups according to the cluster analysis (Cluster 1, n=10; Cluster 2, n=10). 
Three-dimensional gait analysis was conducted where GDI, GPS and GVS (pelvic tilt/obliquity; 
hip flexion-extension/ adduction-abduction/ rotation; knee flexion-extension; ankle dorsiflexion-
plantarflexion, foot progression angle) were calculated. Cluster 1 group presented lower hip 
flexion-extension and lower pelvic obliquity when compared with Cluster 2 group (p<0.05). 
There was no difference between groups for GDI, GPS total and maximum isometric muscle 
strength of the lower limbs (p>0.05). This study showed that GVS could detect alterations on the 
parameters obtained using three-dimensional gait analysis for those DMD patients separated 
according to motor function regarding pelvic and hip kinematic patterns. The rehabilitation of 
patients with DMD is recommended from the early stages of the disease (as Cluster 1, with > 
MFM) with the hip joint being the therapeutic target. 
Keywords: Duchenne muscular dystrophy, gait, gait disorders, gait profile score 
Abstract
1. Introduction 1 
Individuals with Duchenne Muscular Dystrophy (DMD) present with gait deterioration 2 
and   progressive weakness starting in the hip and knee extensor muscles which overloads several 3 
structures and tissues of the musculoskeletal system (Townsend et al., 2015). Postural kinematic 4 
adaptations such as increased lumbar lordosis and anterior pelvic inclination, knee hyperextension 5 
in the terminal support phase of gait, and increased hip and ankle flexion during the swing phase, 6 
are necessary for these individuals to maintain their ability to walk even with the increase in the 7 
muscle weakness (de Carvalho et al., 2015; Doglio et al., 2011). Thus, understanding the 8 
kinematic adaptations of the gait of DMD can improve the knowledge of the disease progression 9 
and guide health professionals into the choice of the best therapeutic interventions (Ropars et al., 10 
2016). 11 
Three-dimensional gait analysis is a tool that provides specific quantitative data on gait 12 
patterns through the integration of kinematic and kinetic parameters and is a widely used tool in 13 
clinical research for the evaluation and follow-up of individuals with DMD (Celletti et al., 2013; 14 
Ferreira et al., 2014). In clinical practice, the interpretation of the data obtained by three-15 
dimensional analysis allows the quantification of the functional limitations related with the 16 
disease, guiding decisions such as surgical interventions and / or indication of orthoses. Souza et 17 
al. (2016), for example, found that an ankle foot orthosis (AFO) improved the kinematic and 18 
kinetics parameters of the gait of patients with DMD recommending them for aiding gait in these 19 
individuals (De Souza et al., 2016). 20 
The clinical relevance of three-dimensional gait analysis motivated researchers to develop 21 
indexes capable of synthesizing the data obtained using this very complex tool, facilitating its 22 
comprehension. The most commonly used are the Gillette Gait Index (GGI), the Hip Flexor Index 23 
(HFI), the Gait Deviation Index (GDI), the Gait Profile Score (GPS) and the Gait Variable Score 24 
(GVS) (Beynon et al., 2010; Rasmussen et al., 2015). Among these indexes, GDI and GPS are 25 
global measures of gait variability and are the most sensitive to detect the changes clinically 26 
relevant in the gait deviations of children with neurological and orthopedic disorders (Celletti et 27 
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al., 2013). The GPS, proposed by Baker et al (2009) (Baker et al., 2009), is a compilation of the 28 
root mean squares of the nine gait variable scores (GVS) which is capable of further describing 29 
the joint specific measures of gait variability. The GPS and GVS (nine variables) can be 30 
represented in a movement analysis profile (MAP) (Baker et al., 2009; Ropars et al., 2016). GPS 31 
has already been used to assess the differences in kinematic parameters between boys and girls 32 
with Down's syndrome (Zago et al., 2019). In patients with Charcot-Marie-Tooth, GPS was able 33 
to quantify the degree of impairment of ambulation (Giancarlo Coghe, Massimiliano Pau, Elena 34 
Mamusa, Cinzia Pisano, Federica Corona, Giuseppina Pilloni, Micaela Porta, Giovanni Marrosu, 35 
Alessandro Vannelli, Jessica Frau, Lorena Lorefice, Giuseppe Fenu, 2018). However, GPS, GVS 36 
or MAP has not been used in the evaluation of patients with DMD to determine whether 37 
differences exist between subgroups of the disease. 38 
Earlier work has utilized the GDI in individuals with DMD and  good correlations with 39 
functional alterations were seen when motor function was evaluated by the Gross Motor Function 40 
Measure (GMFM)  (Thomas et al., 2010). Although the latter authors have obtained positive 41 
results between GDI and GMFM, GMFM is not a scale that was developed or used for individuals 42 
with DMD.  43 
One of the scales for DMD is the Motor Function Measure (MFM) (Iwabe et al., 2008) 44 
and thus one would expect to see gait profile differences between the different clusters within the 45 
MFM. Since DMD is a progressive disease, it is well known that muscle strength and abilities, 46 
obtained through MFM, decrease day by day (Mcdonald et al., 2013; Pizzato et al., 2014). In this 47 
context, we seeked to understand how these variables influence the kinematic parameters of gait 48 
and vice-versa. Thus, this study aimed to evaluate the applicability of the GDI and the GPS in 49 
patients with DMD, using the MFM score levels as a clustering factor. In our hypotheses, GDI 50 
and GPS will be considered a good index to use in the clinical practice if they can answer both 51 
questions: a) if we have 2 DMD groups with different motor abilities, GDI and GPS should detect 52 
deviations of the gait parameters between them; b)  if differences between the groups can be 53 
detected, the GVS will be able to show which kinematics of the joints are different.  54 
2. Methods  55 
 56 
2.1 Sample 57 
Twenty walking male individuals with DMD, aged between 4 and 12 years, were included in 58 
the study. The inclusion criteria were: 1) confirmed DMD diagnosis (by clinical history, genetic 59 
testing and muscle biopsy), 2) independent walking and 3) no difficulty understanding the 60 
instructions. Exclusion criteria consisted of presence of other disorders and previous surgical 61 
procedures. This study was approved by the Ethics Committee of the Hospital das Clínicas da 62 
Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (process number 63 
6017/2013). All patients were on treatment with corticosteroids. The parents or caregivers signed 64 
the informed consent form consenting to participation in the study.  65 
2.2 Evaluation procedures 66 
Maximum isometric muscle strength of hip and knee flexor muscles, and extensors, were 67 
tested using a hand-held dynamometer (Lafayette Instrument, Lafayette, US). The dynamometer 68 
was held perpendicular and distally to the tested segment and three measurements, in kilogram 69 
force, were taken for each tested muscle group and for each limb. The greatest of the three values 70 
was used for statistical analysis. Additionally, the passive range of motion (PRoM)(Marques, 71 
2003), 10-meter walking test (10MWT) with shoes, body composition by bioelectrical impedance 72 
analyses and functional performance assessed by MFM (Iwabe et al., 2008).  73 
PRoM was evaluated in the sagittal plane by means of a conventional goniometer following 74 
the methodology proposed by Marques, 2003 (Marques, 2003) Total body composition was 75 
obtained by bioelectrical impedance analysis (BIA), following manufacturer's recommendations 76 
(Biodynamics-450, São Paulo, Brazil). Prior to the test each participant was instructed to intake 77 
minimal liquid, empty their bladders, avoid alcohol consumption and intense exercise (24 hours 78 
prior to the test), caffeine or food 4 hours prior to the test. Two pairs of sensor pads were placed 79 
on the participants - one on the right wrist and hand and the other one on the right foot and ankle. 80 
We obtained fat-free mass, fat mass, body mass index (BMI) and phase angle (PA). PA depends 81 
on resistance (opposition to the flow of electrical current) and reactance (effect of the capacitive 82 
ability of cell membranes to resist the current). PA is used to quantify cell membrane integrity 83 
(reactance; Xc) and the redistribution of fluid between intra- and extracellular fluid compartments 84 
(resistance; R). PA = tangent arc R/Xc. (Berbigier MC, Pasinato VF, Rubin BA, Moraes RB, 85 
2013). The MFM was applied according to the recommendations contained in the manual; it is 86 
composed of three dimensions, totaling 32 items, which are scored from 0 to 3 according to the 87 
performance of the patient in the execution of the tasks: Dimension 1 (D1): standing position and 88 
transfers, with 13 items; Dimension 2 (D2): axial and proximal motor function, with 12 items; 89 
Dimension 3 (D3): distal motor function, with 7 items (Iwabe et al., 2008). 90 
Following this, three-dimensional gait was assessed using an eight-camera motion analysis 91 
Qualisys Oqus 300 system sampling at 120Hz. Bony prominences were marked using the 92 
Conventional gait model (Helen Hayes marker set) (Kadaba et al., 1990). The reflective markers 93 
were placed on antero-superior iliac crest, mid-point between postero-superior iliac crest, medial 94 
and lateral epicondyle, medial and lateral malleolus, calcaneal tuberosity and mid-point between 95 
second and third metatarsals. Additionally markers on wands over the thigh and leg for were 96 
utilized.  97 
 98 
2.3 Data processing and Statistical Analysis  99 
 100 
Kinematic parameters were computed using Visual3D® (2007) software. The joint's angles 101 
were calculated by a coordinate system according to the Cardan sequence (X, Y, Z), being 102 
considered two body segments. X represents sagittal plane, Y frontal plane and Z transverse plane. 103 
Each individual completed a minimum of eight trials. Mean maximum and minimum gait 104 
kinematic parameter peaks were obtained for each individual considering the entire gait cycle, 105 
normalized to 100%. Subsequently, the GDI, GPS and GVS for each individual were calculated 106 
by GDI-GPS calculator version 3.2 (Baker, n.d.) using the control data provided by Dr Baker in 107 
the calculator.  108 
Patients were grouped using cluster analysis, considering dimension 1 (standing and transfers) 109 
of the MFM scale as a clustering factor. The clusters were obtained in two steps: in the first step 110 
a hierarchical grouping method was used, specifically Ward's algorithm. This method uses a 111 
variance analysis approach to evaluate the distances between clusters, that is, it minimizes the 112 
sum of the squares of any two clusters that can be formed. In the second step the non-hierarchical 113 
cluster was performed using the k-means method with the result of the Ward method as a starting 114 
point (Johnson, Richard A.; Wichern, 2008), the objective is optimize the allocation in the 115 
clusters. After this procedure, it was possible to divide the data into two distinct groups: group 1 116 
(n = 10) with the highest MFM [D1 = 84.10% (11.06%)], and group 2 (n = 10) D1 = 62.64% 117 
(9.58%)].  118 
After the groups were divided, statistical analysis was performed using linear regression 119 
models for comparison between the groups. This model assumes that its residuals have normal 120 
distribution with mean 0 and constant variance. Comparisons between the groups were obtained 121 
by orthogonal contrasts. The results were obtained with the aid of SAS software (Version 9.2), 122 
using PROC GLM. In these analyses a level of significance of 5% was considered and the 123 
adjustments were obtained in SAS software (Version 9.2).  124 
 125 
3 Results 126 
 127 
The groups Cluster 1 and Cluster 2 were obtained according to the MFM score, dimension 1. 128 
As seen in Table 1, the Cluster 1 group (n=10), with the greater MFM, showed: greater phase 129 
angle, smaller execution time in 10-meter walk test and greater total score of MFM (p<0.05) than 130 
the Cluster 2 group (n=10), with the smallest MFM.   131 
 132 
Table 1 133 
 134 
The Cluster 1 group showed greater knee extension passive range of motion than the 135 
Cluster 2 group (p<0.05). For the other values of passive amplitude of joint movement and 136 
maximum isometric muscular strength, there were no significant differences between Cluster 1 137 
and Cluster 2 groups (p> 0.05) (Table 2).  138 
 139 
Table 2 140 
 141 
The Table 3 indicates that Cluster 1 group showed reduced hip flexion-extension and 142 
reduced pelvic obliquity GVS scores than the Cluster 2 group (p<0.05). For the other variables 143 
there were no significant differences between groups (p> 0.05).  144 
 145 
Table 3 146 
 147 
4 Discussion 148 
In patients with DMD, the progressive decline of musculoskeletal function is associated with 149 
gait deviations (Thomas et al., 2010). Our study showed that GVS gave further information of 150 
gait deviations and showed to be a more sensible approach rather than global gait measures as the 151 
GDI and GPS cannot distinguish any differences considering motor abilities (Cluster 1 vs Cluster 152 
2). GVS allowed the identification of kinematic differences in the pelvis and in the hip joint 153 
between the different clusters which would help to inform rehabilitative targets.  154 
As DMD is a progressive disease, pelvic obliquity increases and it was higher in the Cluster 155 
2 group. The Cluster 2 group was composed with children with lower motor abilities and it is 156 
associated with evident gait changes. Even though there was no GPS difference between the 157 
groups, GVS was able to detect the change in pelvic obliquity. In Gaudreault et al. (2010), the 158 
weakness of the hip extensor muscles caused the greater pelvic obliquity facilitating pelvic 159 
progression (Gaudreault et al., 2010) and Doglio et al (2011) observed greater pelvic obliquity in 160 
the double support phase in patients with DMD when compared with a control group (Doglio et 161 
al., 2011). This alteration can be explained considering that in healthy children, pelvic movement 162 
is controlled by the eccentric contraction of the hip abductors which stabilize the hip in a “quasi-163 
static” position while for DMD children, the contralateral pelvis may be lifted by a concentric 164 
contraction of the hip abductors (Gaudreault et al., 2010). In a clinical view, pelvic obliquity and 165 
altered recruitment of pelvic girdle muscles can justify why patients of the Cluster 2 took a longer 166 
time to perform10 MWT than Cluster 1.  167 
The gait deviations on DMD patients can be clustered as low, moderate or advanced, 168 
following the study proposed by Thomas et al. (Thomas et al., 2010). Although the authors 169 
described kinematic alterations using GDI scores, no difference was observed in 10 MWT [11]. 170 
Pizzato et al. (2016) reported that when the rates from the 10 MWT between 2 consecutive 171 
sessions are greater than 1.25, it indicates the borderline between independent gait and to become 172 
a wheelchair user  (Maciel Pizzato et al., 2016). For McDonald et al. (2013) if the 10 MWT is 173 
completed in less than 6 seconds it is associated with maintaining walking during the next 12 174 
months (Mcdonald et al., 2013). Contrastingly, if this time is more than 10-12 seconds, it 175 
represents a higher probability to loss of walking in 12 months (Mcdonald et al., 2013). In this 176 
context, our results demonstrated significant difference in the responses to 10MWT between the 177 
groups and, Cluster 1 group presented almost half time of execution when compared with Cluster 178 
2 although both groups presented time of execution lower than 10 seconds. Following this 179 
reasoning, it could be expected that the patients of the Cluster 2 group will present a higher 180 
probability of losing gait capacity, earlier than the patients of the Cluster 1 group. However, this 181 
would need to be confirmed in a future study to determine whether alterations in the GVS seen in 182 
the proximal segments, 10MWT responses and loss of ambulation are linked.  183 
Although we did not observe significant difference in muscle strength between the groups, 184 
the individuals in Cluster 2 seemed to develop compensatory mechanisms, one of them being an 185 
increase in pelvic obliquity. Unlike the pelvis adaptations, the hip joint showed kinematic 186 
alteration in individuals with mild gait deviations (Thomas et al., 2010). The increase in hip 187 
flexion an obvious kinematic alteration (Doglio et al., 2011), and we could observe greater hip 188 
flexion-extension in the Cluster 2 than the Cluster 1 group. Attias et al. (2017) suggested that the 189 
increased hip flexion during the gait cycle is associated with the shortening of the gastrocnemius 190 
muscle (Attias et al., 2017). This information agreed with our data since a decreased range of the 191 
knee extension was observed in the Cluster 2 group and we observed kinematics alterations of the 192 
hip, knee and ankle during the gait cycle. 193 
The body composition, mainly phase angle showed differences between Cluster 1 vs 194 
Cluster 2. The phase angle has been used as an indicator of cell membrane integrity, so the higher 195 
the phase angle, the greater the cell membrane integrity (reactance) and the lower the phase angle, 196 
the greater redistribution of fluid between intra- and extracellular (Marino et al., 2017). The 197 
review published by Llameset al. (2013) points out that lower phase angle values are associated 198 
with higher risk of postoperative complications, greater severity of congestive heart failure, and 199 
shorter survival in cancer patients (Llames et al., 2013). Despite its clinical relevance, the phase 200 
angle has not been reported yet for patients with DMD. Patients with lower functional score 201 
(Cluster 2 group) had lower phase angle than patients with better functional score (Cluster 1 202 
group) and this result can be explained by the greater cellular degeneration and it characterizes a 203 
more advanced stage of the disease of Cluster 2 group. The data indicate that phase angle may be 204 
useful in assessing the clinical progression and prognosis of DMD, as already reported for other 205 
diseases (Llames et al., 2013). The main limitation of this study is the sample size although 206 
equal groups were in the clusters. Future work should identify whether clustering by gait 207 
pathology would classify the individuals into different groups than the MFM. We also do 208 
not have longitudinal follow-up of these individuals so determining whether these 209 
changes are predictive is a future direction. We also should describe that the individuals 210 
did not wear ankle foot-orthoses during the tests and this may have caused some 211 
individuals to walk worse. However, we assessed whether the gait indexes would be able 212 
to distinguish between groups and thus this should also be repeated in users of AFOs. 213 
There was no control group assed in the paper for the primary reason of distinguishing 214 
between DMD individuals. However, future studies should have a control group range of 215 
parameters to further understand longitudinal changes in these variables with 216 
rehabilitation. 217 
In summary, individuals with DMD with different motor abilities presented with 218 
important alterations in body composition, timed performance tests and kinematic alterations of 219 
the pelvic girdle during gait. The biomechanical changes observed in the hip joint of patients with 220 
DMD may suggest therapeutic strategies as maintain the hip extension function and the flexibility 221 
of the hip flexors. The kinematic findings help the therapeutic direction, as the therapeutic 222 
interventions can affect the kinetics findings. For example, corticosteroid intervention improved 223 
kinematics of the hip joint [28]. These authors suggested that hip joint kinetics, which represents 224 
an initial marker of proximal weakness and it is sensitive to interventions, should be studied for 225 
its reliability, feasibility and applicability as outcome measures for new therapies in DMD. In this 226 
sense, the results of the present study indicate that gait variable score allows the detection of 227 
proximal kinematic changes in pelvis and hip even in the patients with more preserved motor 228 
function, assessed by MFM and would be a useful measure to consider for longitudinal 229 
assessments of individuals with DMD 230 
 231 
 232 
6. Conclusion 233 
This study showed that global measures of gait such as the GDI and GPS did not detect alterations 234 
on the parameters obtained using three-dimensional gait analysis for those individuals with DMD 235 
separated according to motor function. However, the gait variable score highlighted where those 236 
changes were and would be a useful tool to be used for longitudinal assessments in these 237 
individuals. The impairments identified the hip joint as a target for rehabilitation in individuals 238 
with DMD in the early stages of the disease.  239 
 240 
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Table 1: Sample characterization, according Cluster 1 group and Cluster 2 group.  
 Cluster 1 (>MFM; n=10) Cluster 2 (<MFM; n=10) 
Age (years) 6.7 (1.9) 8.4 (2.5) 
Mass (kg) 24.6 (7.3) 33.2 (16.0) 
Height  (m) 1.2 (1.1) 1.3 (1.1) 
BMI (kg/m2) 17.8 (2.0) 19.8 (5.7) 
Fat free mass (kg) 20.8 (3.5) 23.3 (7.7) 
Fat mass (kg) 6.2 (2.4) 11.4 (8.7) 
Phase Angle  (º) 3.7 (0.6)* 3.0 (0.7) 
10-MWT (s) 5.1 (1.2)* 9.3 (3.6) 
D1- MFM (%) 87.2 (5.6)* 57.3 (16.2) 
MFM total score (%) 94.2* (2.7) 80.6 (7.9) 
*p<0.05 when compared to Cluster 2. BMI: body mass index. 10-MWT: 10 meter walk test. 
D1-MFM: dimension 1 of motor function measure scale.   
 
Table 1
Table 2: Passive range of motion (PRoM) and maximum isometric muscle strength, to Cluster 1 
group and Cluster 2 group.  
 Cluster 1 (>MFM; n=10) Cluster 2 (<MFM; n=10) 
PRoM (º)   
Hip extension 10.8 (4.2) 9.5 (3.4) 
Hip flexion 125.4 (10.9) 121.0 (12.8) 
Knee extension 1.0 (1.7)* -2.2 (4.1) 
Knee flexion 136.6 (8.4) 131.8 (11.7) 
Dorsiflexion (KF) 5.3 (8.3) 1.2 (9.6) 
Dorsiflexion (KE) 2.1 (10.1) 0.6 (12.5) 
Plantar flexion  64.8 (13.9) 54.8 (14.7) 
Maximum isometric muscle 
strength (Kgf) 
  
Hip flexors  6.5 (3.3) 5.0 (1.8) 
Knee flexors  8.5 (4.3) 7.5 (3.3) 
Knee Extensors  8.4 (6.7) 5.4 (2.4) 
*p<0.05 when compared to Cluster 2. KF – Knee in flexion. KE – knee in extension. MFM: 




Table 3: Gait profile index (GDI) and Gait profile score (GPS)/ Gait variable scores (GVS) to 
groups Cluster 1 and Cluster 2. 
 Cluster 1 (>MFM; n=10) Cluster 2 (<MFM; n=10) 
GDI 81.5 (5.0) 76.1 (8.8) 
GPS total (º) 8.8 (1.4) 10.7 (2.9) 
Pelvic tilt (º) 6.2 (3.4) 10.4 (6.9) 
Pelvic obliquity (º) 2.2 (1.3)* 3.7 (1.7) 
Pelvic rotation  (º) 4.4 (1.7) 5.0 (3.8) 
Hip Flexion-extension (º) 6.7 (1.4) * 12.2 (5.4) 
Hip Adduction-Abduction (º) 3.2 (1.1) 4.7 (3.2) 
Hip rotation (º) 13.5 (5.9) 11.9 (10.8) 
Knee Flexion-extension (º) 12.3 (1.6) 11.3 (4.0) 
Ankle Dorsiflexion-plantarflexion (º) 14.2 (4.7) 11.8 (11.2) 
Foot progression angle (º) 11.8 (6.0) 8.5 (5.3) 
* p<0.05 when compared with Cluster 2 group. GDI, GPS and GVS for each individual 




Declarations of interest: none 
 
Conflict of Interest Statement
